论文部分内容阅读
顺铂(cisplatin,CDDP)是近年来癌化学疗法的关键药物之一。但是,由于其毒性作用,临床应用常受到限制。Carboplatin(CBD-CA)是Harrap等1980年开发,1981年试用于临床的第二代铂性抗癌剂。其作用机理与CDDP相同。临床试验显示,抗肿瘤谱和抗肿瘤效果与CDDP基本相同,仍以头颈癌、卵巢癌、肺小,细胞癌等为主要对象。CBDCA的药物动力学与CDDP不同,CDDP的非蛋白结合铂极迅速减少,而CBDCA的非蛋白结合铂的半衰期长达6小时;CDDP的蛋白结合率为90%以上,而CBDCA的蛋白结合率为24%;一日尿中排泄CDDP16
Cisplatin (CDDP) is one of the key drugs in cancer chemotherapy in recent years. However, clinical application is often limited due to its toxic effects. Carboplatin (CBD-CA) is the second generation platinum anticancer agent developed by Harrap et al in 1980 and clinical trial in 1981. Its mechanism of action and CDDP the same. Clinical trials show that anti-tumor spectrum and anti-tumor effect and CDDP basically the same, still head and neck cancer, ovarian cancer, lung small cell carcinoma as the main target. The pharmacokinetics of CBDCA is different from that of CDDP in that the non-protein bound platinum of CDDP rapidly decreases while the half-life of non-protein bound platinum of CBDCA is up to 6 hours. The protein binding rate of CDDP is over 90%, while the protein binding rate of CBDCA is 24%; first-day urinary excretion of CDDP16